Lazcluze (Lazertinib) for Lung Cancer

Overview
Lazcluze is approved by the U.S. Food and Drug Administration (FDA) for the first-line treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) that carries specific epidermal growth factor receptor (EGFR) mutations (exon 19 deletions or exon 21 L858R substitution mutations). To be eligible, a person must have these mutations confirmed by an FDA-approved test. Lazcluze is used in combination with amivantamab (Rybrevant) for this treatment. Lazcluze is also known by its drug name, lazertinib.

Lazcluze belongs to a class of medications called tyrosine kinase inhibitors. It works by blocking EGFR activity, which is often overactive in certain types of lung cancer, leading to the uncontrolled growth and spread of cancer cells. By inhibiting this pathway, Lazcluze helps slow or stop cancer progression.

How do I take it?
Prescribing information states that Lazcluze is taken as an oral tablet once daily, with or without food. It is given in combination with amivantamab, and Lazcluze should be taken before amivantamab if both are taken on the same day. Treatment should continue until the disease progresses or unacceptable side effects occur. Per the label, people are also advised to take anticoagulant medication to prevent blood clots (venous thromboembolic events, or VTE) for the first four months of treatment. Lazcluze should be taken exactly as prescribed by a healthcare provider.

Side effects
Common side effects of Lazcluze taken in combination with amivantamab include rash, nail problems, infusion-related reactions (from amivantamab), musculoskeletal pain, swelling, stomatitis (mouth sores), VTE, paresthesia (numbness or tingling), fatigue, diarrhea, constipation, COVID-19 infection, hemorrhage (bleeding), dry skin, loss of appetite, pruritus (itching), nausea, and eye-related issues.

Rare but serious side effects may include VTE, interstitial lung disease (lung inflammation or scarring), severe skin reactions, eye problems such as keratitis (corneal inflammation), and embryo-fetal toxicity (risks to an unborn baby) if used during pregnancy. 

For more information about this treatment, visit:

Label: Lazcluze — Lazertinib Tablet, Film Coated — DailyMed